(8-OXO-5,6,7,8-TETRAHYDRO-4H-CYCLOPENTA[D][1,2,4]-TRIAZOLO[1,5-A]PYRIMIDIN-2-YL)-ACETIC ACID
- $378 - $777.32
- Product name: (8-OXO-5,6,7,8-TETRAHYDRO-4H-CYCLOPENTA[D][1,2,4]-TRIAZOLO[1,5-A]PYRIMIDIN-2-YL)-ACETIC ACID
- CAS: 842975-51-3
- MF: C10H10N4O3
- MW: 234.21
- EINECS:
- MDL Number:MFCD07186481
- Synonyms:ASINEX-REAG BAS 12403154;(8-OXO-5,6,7,8-TETRAHYDRO-4H-CYCLOPENTA[D][1,2,4]-TRIAZOLO[1,5-A]PYRIMIDIN-2-YL)-ACETIC ACID;(8-Oxo-5,6,7,8-tetrahydro-4H-cyclopenta[d][1,2,4]-triazolo[1,5-a]pyrimidin-2-yl)-;2-(8-Oxo-5,6,7,8-tetrahydro-1H-cyclopenta[d][1,2,4]triazolo[1,5-a]pyrimidin-2-yl)acetic acid;1H-Cyclopenta[d][1,2,4]triazolo[1,5-a]pyrimidine-2-acetic acid, 5,6,7,8-tetrahydro-8-oxo-
2 prices
Selected condition:
Brand
- American Custom Chemicals Corporation
- Matrix Scientific
Package
- 500MG
- 1g
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberCHM0081451
- Product description(8-OXO-5,6,7,8-TETRAHYDRO-4H-CYCLOPENTA[D][1,2,4]-TRIAZOLO[1,5-A]PYRIMIDIN-2-YL)-ACETIC ACID 95.00%
- Packaging500MG
- Price$777.32
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number019484
- Product description(8-Oxo-5,6,7,8-tetrahydro-4H-cyclopenta[d][1,2,4]-triazolo[1,5-a]pyrimidin-2-yl)-acetic acid
- Packaging1g
- Price$378
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
American Custom Chemicals Corporation | CHM0081451 | (8-OXO-5,6,7,8-TETRAHYDRO-4H-CYCLOPENTA[D][1,2,4]-TRIAZOLO[1,5-A]PYRIMIDIN-2-YL)-ACETIC ACID 95.00% | 500MG | $777.32 | 2021-12-16 | Buy |
Matrix Scientific | 019484 | (8-Oxo-5,6,7,8-tetrahydro-4H-cyclopenta[d][1,2,4]-triazolo[1,5-a]pyrimidin-2-yl)-acetic acid | 1g | $378 | 2021-12-16 | Buy |
Properties
Boiling point :643.3±57.0 °C(Predicted)
Density :1.87±0.1 g/cm3(Predicted)
pka :3.35±0.10(Predicted)
Density :1.87±0.1 g/cm3(Predicted)
pka :3.35±0.10(Predicted)
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|